Acurx Pharmaceuticals Inc
Company Profile
Business description
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Contact
259 Liberty Avenue
Staten IslandNY10305
USAT: +1 917 533-1469
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
The best global tech stocks to buy
stocks
Earnings margins to improve for mining specialist
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,114.30 | 79.50 | -0.86% |
| CAC 40 | 8,317.98 | 11.83 | 0.14% |
| DAX 40 | 26,007.63 | 1.10 | 0.00% |
| Dow JONES (US) | 52,786.07 | 628.18 | -1.18% |
| FTSE 100 | 10,811.66 | 10.47 | -0.10% |
| HKSE | 25,317.18 | 95.94 | -0.38% |
| NASDAQ | 26,421.41 | 85.58 | -0.32% |
| Nikkei 225 | 65,269.33 | 1,130.52 | -1.70% |
| NZX 50 Index | 13,792.90 | 149.93 | -1.08% |
| S&P 500 | 7,673.52 | 45.08 | -0.58% |
| S&P/ASX 200 | 8,920.80 | 82.20 | -0.91% |
| SSE Composite Index | 3,940.55 | 7.85 | 0.20% |